home.social

#emapresser — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #emapresser, aggregated by home.social.

  1. If an unusual pattern emerged, the #PRAC performed an in-depth analysis of the reports to quickly identify potential safety issues with #Covid19vaccines.

    The 🇪🇺 pharmacovigilance system showed that it can detect and manage emerging #safety issues quickly.

    #EMAPresser

    🐦🔗: n.respublicae.eu/EMA_News/stat

  2. If an unusual pattern emerged, the #PRAC performed an in-depth analysis of the reports to quickly identify potential safety issues with #Covid19vaccines.

    The 🇪🇺 pharmacovigilance system showed that it can detect and manage emerging #safety issues quickly.

    #EMAPresser

    🐦🔗: n.respublicae.eu/EMA_News/stat

  3. If an unusual pattern emerged, the #PRAC performed an in-depth analysis of the reports to quickly identify potential safety issues with #Covid19vaccines.

    The 🇪🇺 pharmacovigilance system showed that it can detect and manage emerging #safety issues quickly.

    #EMAPresser

    🐦🔗: n.respublicae.eu/EMA_News/stat

  4. We placed extra obligations on the #Covid19vaccine makers.

    They had to provide us with detailed monthly reports on the #safety of their vaccine ➡️ 5⃣6⃣monthly reports were assessed by our safety committee, the #PRAC, until December 2022.

    #EMAPresser

    🐦🔗: n.respublicae.eu/EMA_News/stat

  5. We placed extra obligations on the #Covid19vaccine makers.

    They had to provide us with detailed monthly reports on the #safety of their vaccine ➡️ 5⃣6⃣monthly reports were assessed by our safety committee, the #PRAC, until December 2022.

    #EMAPresser

    🐦🔗: n.respublicae.eu/EMA_News/stat

  6. We placed extra obligations on the #Covid19vaccine makers.

    They had to provide us with detailed monthly reports on the #safety of their vaccine ➡️ 5⃣6⃣monthly reports were assessed by our safety committee, the #PRAC, until December 2022.

    #EMAPresser

    🐦🔗: n.respublicae.eu/EMA_News/stat

  7. #RealWorldData on the #Mpox vaccine show that it is effective, especially after 2⃣ doses.

    Discussions are ongoing with developers of other vaccines for Mpox and other viruses of the same type.

    #EMAPresser

    🐦🔗: n.respublicae.eu/EMA_News/stat

  8. This autumn, EMA became the 1st regulator in the 🌍 to approve #Beyfortus, a monoclonal antibody to prevent serious lower respiratory tract disease caused by #RSV in newborns & children. #EMAPresser

    🐦🔗: n.respublicae.eu/EMA_News/stat